Corbus Pharmaceuticals Appoints Nishant Saxena as CBO and Announces Phase 1/2 CRB-701 Data Webcast

On May 21, 2026, Corbus Pharmaceuticals Holdings, Inc. entered into an employment agreement with Nishant Saxena, appointing him as Chief Business Officer. The agreement features a two-year term with an annual base salary of $470,000 and a target annual bonus of up to 40%. Mr. Saxena was granted 192,300 stock options and 58,300 restricted stock units, both subject to four-year vesting schedules. Additionally, on May 19, 2026, the company granted initial equity awards to Brent Pfeiffenberger following his appointment to the Board of Directors, consisting of 24,700 stock options and 7,500 restricted stock units. The company also announced it will host a conference call and webcast on May 26, 2026, to discuss clinical data from its Phase 1/2 study of CRB-701, an Nectin-4 targeting drug. The filing details standard severance provisions, including a 'Change in Control Period' which provides for 18 months of salary and accelerated equity vesting if termination occurs under specific conditions related to a corporate change in ownership.